U.S. markets close in 6 hours 19 minutes

MERCK Kommanditgesellschaft auf Aktien (MKGAF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
176.50-7.51 (-4.08%)
As of 2:33PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close184.01
Open176.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range176.50 - 176.50
52 Week Range111.95 - 190.25
Volume2
Avg. Volume157
Market Cap76.577B
Beta (5Y Monthly)0.49
PE Ratio (TTM)27.79
EPS (TTM)6.35
Earnings DateN/A
Forward Dividend & Yield1.69 (0.92%)
Ex-Dividend DateApr 26, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?
    Motley Fool

    This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?

    Will the timely new product position Merck KGaA as an upstream supplier for the entire mRNA medicine world and allow it to reap the benefits, or is it unlikely to reward shareholders? To start, let's quickly review the scientific concepts at hand so that it's clear why Merck KGaA's new product is worth knowing about. As you may know, lipid molecules don't dissolve in water.

  • MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript
    Motley Fool

    MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript

    MKKGY earnings call for the period ending March 31, 2021.

  • Reuters

    UPDATE 1-Lab supplier Merck KGaA says U.S. Defense Production Act poses challenge

    Merck KGaA on Wednesday said that U.S. regulations that give priority to U.S. government contracts to purchase COVID-19 vaccines are a challenge as it seeks to meet soaring demand for its lab equipment and supplies across the globe. She said U.S. law required that a preference be given to so-called rated state orders for COVID-19 programmes over any other orders. "For us, all our customers and all the other COVID-19 programmes are very crucial and we are making capacity expansion a top priority of our agenda," she said, pointing to investment projects both in the United States and Europe.